Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher
CEO, Jon Pilcher
Source: Neuren Pharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Neuren Pharmaceuticals (NEU) submits an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for NNZ-2591
  • This application is being made to treat Phelan-McDermid syndrome which is a neurodevelopmental disorder associated with a deletion of chromosome 22
  • Following approval of the application, Neuren will undertake a phase two trial in children with Phelan-McDermid syndrome in the US
  • Neuren has filed an IND application for NNZ-2591 to treat Angelman syndrome and is in the process of finalising an application for Pitt Hopkins syndrome
  • Shares in Neuren are down a slight 0.98 per cent on the market and are trading at $2.03 at 12:57 pm AEST

Neuren Pharmaceuticals (NEU) has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for NNZ-2591.

This application is being made to treat Phelan-McDermid syndrome (PMS) which is a neurodevelopmental disorder associated with a deletion of chromosome 22, resulting in the loss of function of the SHANK3 gene.

The most common characteristics include intellectual disability, epilepsy, delayed or absent speech, motor delays, low muscle tone and autism with roughly 75 per cent of people with PMS diagnosed with autism.

Following approval of the application, Neuren will undertake a phase two trial in children with PMS in the US.

CEO John Pilcher is pleased with the milestone reached.

“This is another important milestone achieved in our plan to develop NNZ-2591 for multiple serious neurological conditions,” Mr Pilcher said.

“We are eager to start the phase two trial in children with Phelan-McDermid syndrome, which we hope will demonstrate the potential for NNZ-2591 to provide an urgently needed treatment option.”

Neuren has already filed an IND application for NNZ-2591 to treat Angelman syndrome and is in the process of finalising an application for Pitt Hopkins syndrome.

The aim of NNZ-2591 is to mimic the normal function of the brain and help control and normalise the biological process.

Shares in Neuren are down a slight 0.98 per cent on the market and are trading at $2.03 at 12:57 pm AEST.

NEU by the numbers
More From The Market Herald

" Race Oncology (ASX:RAC) reports $1.8m in cash outflows

Race Oncology (ASX:RAC) reports $1.8 million in cash outflows
Imugene (ASX:IMU) - CEO, Leslie Chong

" Imugene (ASX:IMU) signs clinical trial agreement with Roche for lung cancer

Imugene (ASX:IMU) signs a clinical trial supply agreement with Roche to evaluate the combination of treatments…
Fiji Kava (ASZ:FIJ) - CEO and Managing Director, Dr Anthony Noble

" Fiji Kava (ASX:FIJ) hits quarterly revenue record

Fiji Kava (ASX:FIJ) has tabled a record quarterly revenue of $476,531 for the December quarter, up…